Arcus Biosciences Reports Promising Results in Phase Ib/II Trial for Metastatic Colorectal Cancer

In the recently conducted Phase Ib/II trial ARC-9 (NCT04660812), evaluating the safety and efficacy of Etrumadenant (E) combined with zimberelimab (Z) and FOLFOX/bevacizumab (bev) regimens or novel therapies in patients with metastatic colorectal cancer (mCRC), some significant findings have been reported.

The trial involved 112 patients, and the results as of November 13, 2023, with a median follow-up of 20.4 months, show that the EZFB combination demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to the regimen containing regorafenib (rego).

Specifically, the EZFB combination showed a median PFS of 6.2 months, with a Hazard Ratio (HR) of 0.27 and a 95% Confidence Interval (CI) of 0.17-0.43, indicating a substantial improvement compared to the rego regimen, which had a median PFS of 2.1 months.

In terms of overall survival, the EZFB combination exhibited a median OS of 19.7 months, with a HR of 0.37 and a 95% CI of 0.22-0.63, showing a significant advantage over the rego regimen, which had a median OS of 9.5 months.

Additionally, the safety profile of the EZFB combination was found to be acceptable and consistent with the known FOLFOX/bev toxicity profile, with no deaths related to study treatment in either arm.

The findings from this trial suggest that the EZFB combination has the potential to significantly improve efficacy outcomes compared to the rego regimen in refractory mCRC patients who were previously treated with 5-FU, oxaliplatin, and irinotecan regimens, without any unexpected toxicities.

These results indicate a promising direction for further investigation and potential clinical application of the EZFB combination in the treatment of metastatic colorectal cancer. The market has reacted to these announcements by moving the company's shares -0.9% to a price of $16.13. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.